Eurobio Scientific Faces Mandatory Buyout Tender Offer Filing
A public withdrawal offer followed by a mandatory squeeze-out has been filed targeting Eurobio Scientific shares, according to a Sept. 24 disclosure.
A formal tender offer aimed at delisting Eurobio Scientific has been filed, with the process to include a mandatory squeeze-out of remaining minority shareholders, the French diagnostics company disclosed in a regulatory communiqué dated September 24, 2026.
The filing initiates a two-stage procedure common under French securities law: a public withdrawal offer, known as an offre publique de retrait, followed by a retrait obligatoire — a compulsory buyout mechanism that forces out shareholders who did not tender their shares voluntarily once the acquirer crosses the required ownership threshold.
Read more Ormat Wins $35M DOE Grant for Geothermal Projects in Nevada, Utah →
The squeeze-out mechanism is typically triggered when a controlling shareholder holds at least 90 percent of voting rights in a listed company, allowing the majority owner to acquire remaining shares at the same price offered in the initial tender, subject to regulatory review by French markets authority AMF.
Eurobio Scientific, a specialty diagnostics and life sciences distribution company listed on Euronext Paris, has been subject to consolidation activity in recent years as larger players have sought to absorb niche diagnostics firms across European markets. The mandatory buyout filing signals that the controlling shareholder has accumulated sufficient ownership to proceed with full delisting.
No additional financial terms or timeline specifics beyond the September 24 filing date were provided in the disclosure. Continue reading at GlobeNewswire - Industry News on Financial Services.
